Crinetics Pharmaceuticals to Present at H.C. Wainwright Global Investment Conference

Article Stock Quotes (1)

FREE Breaking News Alerts from StreetInsider.com!

StreetInsider.com Top Tickers, 8/12/2026

1. CRWV
2. SMCI
3. LITE
4. ONON
5. CAVA

6. QNT
7. NCMI
8. FOCL
9. TME
10. ETOR

Get Alerts CRNX Hot Sheet

Price: $84.36 --0%

Overall Analyst Rating:
SELL (= Flat)

Join SI Premium – FREE

SAN DIEGO, Sept. 03, 2019 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX), a clinical stage pharmaceutical company focused on the discovery, development and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors, today announced that Scott Struthers, Ph.D., Founder and Chief Executive Officer, will present an overview of the company at the 21st Annual H.C. Wainwright Global Investment Conference. The presentation will take place on Tuesday, September 10, 2019 at 8:45 a.m. ET (5:45 a.m. PT) at the Lotte New York Palace in New York City.

A live audio webcast and replay of the presentation will be available in the Investors section on the company’s website at www.crinetics.com.

About Crinetics Pharmaceuticals

Crinetics Pharmaceuticals is a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. The company’s lead product candidate, CRN00808, is an oral selective nonpeptide somatostatin receptor type 2 biased agonist undergoing two Phase 2 clinical trials for the treatment of acromegaly, an orphan disease affecting more than 25,000 people in the United States. Crinetics’ second oral product development candidate, CRN01941, has entered the clinic for the treatment of neuroendocrine tumors. The company is also developing oral nonpeptide somatostatin agonists for hyperinsulinism, as well as oral nonpeptide ACTH antagonists for the treatment of Cushing's disease. All of the company’s drug candidates are new chemical entities resulting from in-house drug discovery efforts. For more information, please visit www.crinetics.com.

Contacts:Marc WilsonChief Financial Officer[email protected] (858) 450-6464

Robert H. UhlWestwicke Partners[email protected] (858) 356-5932